Summary
25.38 0.06(0.24%)07/03/2025
Pfizer Inc. (PFE)
PFE reported last earnings on 2025-04-29 after the market. An EPS of $0.92 was observed compared to an estimated EPS of $0.666, resulting in a surprise value of $0.25. A revenue of $13,715 million was observed compared to an estimated revenue of $13,920 million, resulting in a surprise value of $-205 Million.
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.24 | 4.92 | 8.69 | 6.46 | -1.13 | -2.23 | -2.42 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Strong Buy |
| ROE | Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Neutral |
Earnings
| Trading Data | ||
| Close | 25.38 | |
| Open | 25.35 | |
| High | 25.52 | |
| Low | 25.22 | |
| Volume | 27,104,600 | |
| Change | 0.06 | |
| Change % | 0.24 | |
| Avg Volume (20 Days) | 39,044,203 | |
| Volume/Avg Volume (20 Days) Ratio | 0.69 | |
| 52 Week Range | 20.72 - 29.98 | |
| Price vs 52 Week High | -15.35% | |
| Price vs 52 Week Low | 22.52% | |
| Range | 0.00 | |
| Gap Up/Down | -0.01 | |
Profitibility | ||
| Market Capitalization (Mln) | 132,725 | |
| Revenue per share | 11.0067 | |
| Net Income per share | 1.3861 | |
| Dividend Yield | 0.0670 | |
| Dividend Share | 170.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 18.3106 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/05 08:00 EST - seekingalpha.com
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are...
07/05 06:30 EST - fool.com
The Best Dividend Stocks I'd Buy Right Now
Savvy investors know not to overlook the power of dividends. And Warren Buffett, arguably the savviest investor of all, appreciates dividends, too.
The Best Dividend Stocks I'd Buy Right Now
Savvy investors know not to overlook the power of dividends. And Warren Buffett, arguably the savviest investor of all, appreciates dividends, too.
07/04 09:00 EST - 247wallst.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Shares of Pfizer ( NYSE: PFE )Â surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Shares of Pfizer ( NYSE: PFE )Â surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
07/04 07:45 EST - fool.com
2 Stocks to Buy With Less Than $50
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
2 Stocks to Buy With Less Than $50
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
07/04 03:51 EST - fool.com
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028
Since late 2022, no investment trend has been hotter on Wall Street than the evolution of artificial intelligence (AI). Allowing AI-empowered software and systems to make split-second decisions and grow more efficient at their tasks over time is a game-changing technology that offers utility in...
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028
Since late 2022, no investment trend has been hotter on Wall Street than the evolution of artificial intelligence (AI). Allowing AI-empowered software and systems to make split-second decisions and grow more efficient at their tasks over time is a game-changing technology that offers utility in...
07/03 16:33 EST - 247wallst.com
Stocks At All-Time Highs – Grab Your Gains and Buy These 7% Dividend Gems
Investors love dividend stocks, especially those with dependable yields of 7% or higher, because they offer a significant income stream and have substantial total return potential.
Stocks At All-Time Highs – Grab Your Gains and Buy These 7% Dividend Gems
Investors love dividend stocks, especially those with dependable yields of 7% or higher, because they offer a significant income stream and have substantial total return potential.
07/03 09:53 EST - seekingalpha.com
Pfizer: Options Activity Speaks Bullish
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and...
Pfizer: Options Activity Speaks Bullish
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and...
07/03 09:51 EST - zacks.com
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
07/03 08:03 EST - benzinga.com
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
07/03 04:21 EST - fool.com
Is Pfizer Stock a Yield Trap?
When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.
Is Pfizer Stock a Yield Trap?
When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.
07/03 03:51 EST - fool.com
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July
For more than a century, Wall Street has been a bona fide wealth-creating machine. Though other asset classes, including bonds, commodities, and real estate, have also delivered positive long-term returns, none of these other investments has come particularly close to matching the average annual...
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July
For more than a century, Wall Street has been a bona fide wealth-creating machine. Though other asset classes, including bonds, commodities, and real estate, have also delivered positive long-term returns, none of these other investments has come particularly close to matching the average annual...
07/02 18:46 EST - zacks.com
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
07/01 11:06 EST - globenewswire.com
Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North America leading. New launches by...
Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North America leading. New launches by...
07/01 10:36 EST - zacks.com
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
07/01 10:01 EST - zacks.com
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
06/29 21:23 EST - prnewswire.com
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass. , June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with...
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass. , June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with...
06/28 06:35 EST - fool.com
3 No-Brainer Stocks to Buy for Under $100 Right Now
What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.
3 No-Brainer Stocks to Buy for Under $100 Right Now
What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.
06/27 16:15 EST - 247wallst.com
5 Recession-Proof Dividend Stocks With Yields Over 6%
When the economy is barreling toward a recession, investors' first line of defense might be to abandon ship altogether.
5 Recession-Proof Dividend Stocks With Yields Over 6%
When the economy is barreling toward a recession, investors' first line of defense might be to abandon ship altogether.
06/27 12:00 EST - zacks.com
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.